AMR.Solutions
Menu-01-01

R&D Insight

Looking forward: The global pre-clinical antibacterial pipeline / How will we care for these precious jewels?

​Dear All, Long note alert! There are two deep and deeply connected topics to share today. Refresh your coffee and settle in… Today’s first topic: Adding to the recent reviews of the clinical stage pipeline for both traditional products (link to the Sep 2019 Pew Charitable Trusts summary), and non-traditional products (link to an Aug 2019 newsletter summarizing

Read More »
24 November 2019 No Comments

An apple a day (used to) keep the doctor away

Dear All: OK … enough with bad news, at least for today. In today’s edition of XKCD (link), we learn about resistance to apples and the need to use good apple stewardship. Image reproduced with permission from https://xkcd.com/2161/ If you don’t read XKCD, you should! All best wishes, –jr John H. Rex, MD | Chief Medical

Read More »
11 June 2019 No Comments

AMR stays on the G20’s to-do list with calls for Push and Pull mechanisms

Aside: Please look closely at the forward calendar. In addition to two new webinars from GARDP’s REVIVE project, there is a meeting in Thailand in December that focuses on alternatives to antibiotics. I’m told that the program is primarily focused on veterinary and agricultural uses, but previous year’s attendees have found the discussion to have broad application

Read More »
5 July 2019 No Comments

Commissioner Gottleib (New FDA initiatives, need for Pull incentives) + updated Pew pipeline analyses

Dear All: It was a HUGE day at the Pew Charitable Trusts today! First, Commissioner Scott Gottleib gave a superb and very exciting speech. You can either read or listen to the entire speech. There is also a panel discussion after his talk that is worth replaying. Here are some highlights from Commissioner Gottleib’s talk: FDA is working to coordinate

Read More »
14 September 2018 No Comments

BARDA’s DRIVe is looking for you! Can you help them run a venture fund?

Dear All: I’ve written before about BARDA’s DRIVe initiative (Division of Research Innovation and Ventures, launched June 2018) that seeks to develop countermeasures for chemical, biological, radiological, and nuclear threats, as well as for pandemic influenza and emerging infectious diseases.  As a core part of this work, DRIVe Ventures seeks to link innovators and investors through creation of a VC-like

Read More »
22 January 2019 No Comments

Scary, Scarier, Scariest (Part 2): What can YOU do about it?

Long note alert— apologies! Get a cup of coffee and settle in… Dear All: My 22 Apr 2019 note entitled Scary, Scarier, Scariest: Achaogen / FT editorial / CBS “60 Minutes” on AMR (link) caused a number of you to write expressing your related concerns and frustrations. Many thanks for those thoughts! A core theme in those

Read More »
5 May 2019 No Comments

JPIAMR: Network proposal call; BARDA: DRIVe Accelerator call

Dear All: I trust you are now home after ECCMID in Madrid … it was an excellent meeting. Two new funding opportunities have recently crossed my radar: brief summaries and one key link for each are here with some further details below my signature.  EU JPIAMR funding call: As part of its Virtual Research Institute

Read More »
7 May 2018 No Comments

Clever pipeline visualization from Pew + New guidance documents from FDA

Dear All, Two very brief notes today… First, Pew Trusts continues to work to provide ways to understand the antibiotic pipeline. Building on their ongoing surveys (link), their latest contribution is a clever visualization tool that shows how antibiotics have moved forwards, backwards, and/or stopped during the period 2014-2018. Go here to see it in action and prepare to

Read More »
5 August 2019 No Comments
Scroll to Top